AspirinThird Party Manufacturing in India

Aspirin (acetylsalicylic acid) works by irreversibly acetylating and inhibiting the cyclooxygenase (COX-1 and COX-2) enzymes, which catalyze the conversion of arachidonic acid into prostaglandin H₂, the precursor to prostaglandins, prostacyclin, and thromboxanes. By blocking this step, aspirin reduces the production of prostaglandins that mediate pain, inflammation, and fever. The key distinction of aspirin from other NSAIDs lies in its irreversible binding — it covalently modifies the COX enzyme through acetylation of a serine residue in the active site. This is particularly significant for the antiplatelet effect: at low gastro-resistant doses of 75–81 mg, aspirin selectively inhibits COX-1 in platelets, preventing the formation of thromboxane A₂, a potent vasoconstrictor and platelet aggregator. Because platelets are anuclear and cannot synthesize new COX enzymes, the antiplatelet effect persists for their entire lifespan of 7 to 10 days. The gastro-resistant (enteric-coated) formulation is specifically designed to bypass the acidic environment of the stomach and release aspirin in the small intestine, reducing direct mucosal irritation while preserving systemic antiplatelet efficacy. This formulation achieves reliable platelet inhibition with reduced gastric adverse effects, making it suitable for long-term daily cardiovascular prophylaxis.

Therapeutic Uses

Aspirin (Gastro-Resistant) is primarily prescribed for cardiovascular prophylaxis:

• Secondary Prevention of Myocardial Infarction: Reduces the risk of recurrent heart attacks and cardiovascular death in patients with established coronary artery disease.
• Stroke Prevention: Lowers the incidence of ischemic stroke and transient ischemic attacks in patients with a history of cerebrovascular events.
• Primary Prevention in High-Risk Patients: Recommended for individuals aged 40–59 with a 10% or greater 10-year cardiovascular disease risk, where the benefits of preventing a first heart attack or stroke outweigh the bleeding risk.
• Post-Procedural Antithrombotic Therapy: Used following coronary artery bypass grafting, percutaneous coronary intervention, and stent placement, often as part of dual antiplatelet therapy with clopidogrel.
• Unstable Angina: Reduces the risk of progression to myocardial infarction in patients with unstable angina.
• Peripheral Arterial Disease: Provides atherothrombotic risk reduction in patients with established peripheral vascular disease.

Why Manufacturers Choose Aspirin (Gastro-Resistant)

Aspirin in its gastro-resistant formulation is a foundational product for any pharmaceutical manufacturer specializing in cardiac care. The low-dose enteric-coated tablet is the standard of care for long-term cardiovascular prevention worldwide, ensuring stable, high-volume demand across both domestic and export markets. Indian third-party manufacturers invest in specialized coating technology to produce enteric-coated tablets that comply with IP, BP, and USP dissolution specifications. The film coating must reliably protect the tablet core from gastric acid while ensuring complete release in the intestinal pH environment. This technical requirement creates a higher barrier to entry compared to plain tablets, meaning manufacturers with proven enteric coating capabilities command premium pricing. With cardiovascular disease remaining the leading cause of mortality globally, the demand for gastro-resistant aspirin tablets from PCD franchise operators, hospital supply chains, and export partners continues to grow steadily. This makes Aspirin gastro-resistant one of the most commercially important cardiac formulations for third party manufacturing in India.